Skip to Content
Due to a recent surge in pediatric RSV and flu, we are allowing only visitors 18 years of age and older in our general inpatient (hospital) settings at this time for the safety of our patients, in line with Illinois Department of Public Health guidance. Read More

Clinical Trials

Alopecia Areata
Aim: This new clinical trial is studying how to treat patients with alopecia areata with an oral medication. A Phase 2B/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of PF-06651600 in Adult and Adolescent Alopecia Areata Subjects with 50% or Greater Scalp Hair Loss as well as an open label multi-center, long- term study investigating the safety and efficacy of PF-06651600 in adult and adolescent participants with alopecia areata of 25% or more hair loss.

  • Patients must be 12 years and older
  • Patient must have 25% or more hair loss
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Alopecia Areata
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH19-013 and EH19-267
Sponsor: Pfizer
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Alopecia Areata Clinical Trial"
Open to Enrollment: Yes

Hidradenitis Suppurativa
Aim: This new clinical trial is a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous injections of secukinumab dose regimens in adult patients with moderate to severe hidradenitis suppurativa

  • Patients must be 18 years and older
  • Patient must have 5 or more active draining lesions of HS in two anatomical body locations
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Hidradenitis Suppurativa
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH19-193
Sponsor: Novartis
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Hidradenitis Suppurativa Clinical Trial"
Open to Enrollment: Yes

Hidradenitis Suppurativa
Aim: This new clinical trial is a randomized, double-blind, placebo-controlled, phase 2 study to evaluate upadacitinib in study participants with moderate to severe hidradenitis suppurativa

  • Patients must be 18 years and older
  • Patient must have 5 or more active draining lesions of HS in two anatomical body locations
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Hidradenitis Suppurativa
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH20-241
Sponsor: AbbVie
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Hidradenitis Suppurativa Clinical Trial"
Open to Enrollment: Not yet

Hidradenitis Suppurativa
Aim: This new clinical trial is a phase 3, randomized, placebo controlled multicenter study evaluating the efficacy and safety of Bimekizumab in study participants with moderate to severe hidradenitis suppurativa.

  • Patients must be 18 years and older
  • Patient must have 5 or more active draining lesions of HS in two anatomical body locations
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Hidradenitis Suppurativa
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH20-108
Sponsor: UCB
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Hidradenitis Suppurativa Clinical Trial"
Open to Enrollment: Not yet

Hidradenitis Suppurativa
Aim: This new clinical trial is a phase 3, randomized, placebo controlled multicenter study evaluating the efficacy and safety of Bimekizumab in study participants with moderate to severe hidradenitis suppurativa.

  • Patients must be 18 years and older
  • Patient must have 5 or more active draining lesions of HS in two anatomical body locations
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Hidradenitis Suppurativa
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH19-353
Sponsor: Pfizer
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Hidradenitis Suppurativa Clinical Trial"
Open to Enrollment:Yes

Atopic Dermatitis/Eczema
Aim:: This new study is a prospective, observational, and longitudinal study in pediatric patients with moderate to severe atopic dermatitis

  • Patients must be younger than 12 years old
  • Patient must have moderate to severe atopic dermatitis
  • Patients must have the ability to make multiple office visits over the course of the study

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH20-204 and EH20-205
Sponsor: Sanofi
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Not yet

Atopic Dermatitis/Eczema
Aim:: This new clinical trial is a phase 3 pivotal and open label extension to assess the efficacy and safety of injectable Nemolizumab in moderate to severe atopic dermatitis subjects and associated pruritus.

  • Patients must be 18 years and older
  • Patient must have a diagnosis of at least 6 months of eczema or atopic dermatitis in the past 6 months, 10% body surface of covered eczema and tried and failed past treatments.
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH19-265 and EH20-211
Sponsor: Galderma
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Yes

Atopic Dermatitis/Eczema
Aim: This new clinical trial is a randomized double-blind, placebo controlled efficacy study of oral Nerokinin-1 Receptor Antagonist VLY-686 in patients with atopic dermatitis

  • Patients must be 18 years and older
  • Patient must have a diagnosis of eczema with the pruritus/itch component.
  • Tried and failed previous topical medications
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Stephanie Mehlis, MD
IRB Approval Number: EH20-041
Sponsor: Vanda
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line "Dermatology Eczema Clinical Trial"
Open to Enrollment: Currently paused

Atopic Dermatitis/Eczema
Aim: This new clinical trial is a phase 3 randomized placebo-controlled, double-blind study to evaluate upadacitinib in combination with topical corticosteroids in adolescent subjects with moderate to severe atopic dermatitis.

  • Patients must be 12-18 years old
  • Patient must have a diagnosis of at least 6 months of eczema or atopic dermatitis in the past 6 months, 10% body surface of covered eczema and tried and failed past treatments.
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH18-317
Sponsor: AbbVie
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Yes

Atopic Dermatitis/Eczema
Aim: This new clinical trial is a phase 3 randomized placebo-controlled, double-blind study to evaluate upadacitinib in adolescent subjects with moderate to severe atopic dermatitis.

  • Patients must be 12-18 years old
  • Patient must have a diagnosis of at least 6 months of eczema or atopic dermatitis in the past 6 months, 10% body surface of covered eczema and tried and failed past treatments.
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH18-293
Sponsor: AbbVie
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Yes

Atopic Dermatitis/Eczema
Aim:: This new clinical trial is a phase 3 randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of lebrikizumab in patients with moderate to severe atopic dermatitis

  • Patients must be 12 years and older
  • Patient must have a diagnosis of at least 1 year of eczema or atopic dermatitis in the past 6 months, 10% body surface of covered eczema and tried and failed past treatments.
  • Patients must have the ability to make multiple office visits with blood draws

Diagnosis: Atopic Dermatitis/Eczema
Principal Investigator: Joel Joyce, MD
IRB Approval Number: EH20-203
Sponsor: Dermira
Contact: Interested patients should contact our Dermatology Clinical Trials Unit at 847.663.8530 or email derm_ctu@northshore.org and including the subject line"Dermatology Eczema Clinical Trial"
Open to Enrollment: Not yet